The gastric pacemaker is a new obesity treatment, which pleases by its simplicity and obvious lack of complications on the nutritional level. Its long-term efficacy is however to be confirmed and the criterions of the patients' selection to be defined. The rimonabant is a selective antagonist of the cannabinoid CBI receptor, able to reduce the quantity of the total food intake, and especially the greasy one. The first results on the short term look promising. The multiplication of food pyramids is the consequence of the scientific knowledge development in the nutritional field. On this basis, new pyramids are adapted, depending on the therapeutic objectives (weight loss, cardiovascular risk) and allowing either quantity or quality food. The taking charge of patients in group and according to the therapeutic education criterions makes easy a relation between the medical team and patients and allows these latters a better awareness of their disease and its long term treatment.